Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04823585
Other study ID # HUS/686/2020
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date August 12, 2021
Est. completion date December 31, 2025

Study information

Verified date February 2024
Source Helsinki University Central Hospital
Contact Sanna Toppila-Salmi, MD PhD, PI
Phone +358505431421
Email sanna.salmi@helsinki.fi
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Primary objective: to investigate the efficacy of Mepolizumab 100 milligram (mg) every month compared to placebo in reducing validated Sinonasal Outcome Test -22 score and on reducing endoscopic Nasal Polyp Score. The participants have a triad of chronic rhinosinusitis with nasal polyps (CRSwNP), asthma and non-steroidal anti-inflammatory drug exacerbated respiratory disease (NERD). The investigators will evaluate whether mepolizumab reduces the need for increased drug dosage (topical corticosteroid or bronchodilator dosage) and improves lung and nasal function more effectively than placebo. This first visit ensures the inclusion and exclusion criteria of the subject. If necessary, NERD will be verified by an ASA challenge test at a second additional visit. Participants have also 6 visits, on four of which subcutaneous injection of the study product is administered. During visits, a clinical examination, airway function tests, and nasal, blood, urine, and stool samples are also taken to elucidate predictive biomarkers of severely symptomatic NERD patients.


Recruitment information / eligibility

Status Recruiting
Enrollment 110
Est. completion date December 31, 2025
Est. primary completion date December 31, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: - =18 years of age - Exacerbation of respiratory symptoms by acetylsalicylic acid (ASA) or another NSAID. (NERD will be verified by another visit if necessary). - chronic rhinosinusitis with bilateral polyps. Endoscopic bilateral nasal polyp score of at least 5 (out of 8), with a minimum score of 2 in each nasal cavity - Lund Mackay score =12 (maximum 24) of sinus computed tomography (CT) or cone beam (CBCT) scans. The new sinus CT/CBCT scans are needed if the previous sinus CT/CBCT scans have been performed over 36 months before recruitment visit or if there is a suspicion of complication of CRS (f.ex. mucocele, invasive fungal rhinosinusitis). Pregnant and breast-feeding subject will be excluded. Females of Reproductive Potential (FRPs) who are not pregnant or breast-feeding may be enrolled. FRPs need to perform pregnancy test prior to the CT/CBCT scans. If subject is already on contraception prior to the study this should be continued. The data of previous sinus CT/CBCT scans will be used if previous sinus CT/CBCT scans have been performed =36 months prior to recruitment visit. The clinical information of sinus CT/CBCT scans is critical to enrolling appropriate subjects for the research and cannot readily be obtained another way. The radiation dose of sinus CT/CBCT scans is less than 0.1 mSv, which corresponds to less than 10 days of natural background radiation in Finland. This dose has not been shown to increase the cancer risk. - =1 previous CRS-surgery. Note that the last CRS-surgery must have been performed at least 6 months before 1st visit - SNOT-22 =25 - At least one other symptom, such as partial loss of smell (hyposmia), nasal obstruction, total loss of smell (anosmia), or anterior or posterior rhinorrhea - patient should have a history of at least one exacerbation during the past two years e.g. at least one criterion must be fulfilled of the following list during the past two years =1 oral corticosteroids; =3 antibiotic courses; =1 CRS-operation; = 1 asthma hospitalization. In patients with contraindications of previously listed treatment or continuous oral steroids, additional criteria are not required. - Asthma diagnosis (patient has the National Social Insurance Institution´s reimbursement right for asthma medication) - Peripheral blood eosinophils (PBEos) >300 cells/ul at visit 1 OR (PBEos >150 cells/ul at visit 1 AND a history of PBEos >300 cells/ul during the past 12 months). A history of Nasal polyp tissue eosinophilia (NPeos) =30% during the past 12 months is a supportive criterion. Exclusion Criteria: - Age <18 years - Age > 70 years - CRS-surgery < 6 months before 1st visit - pregnancy/ breastfeeding. FRPs need to perform pregnancy test prior to the CT/CBCT scans. If subject is already on contraception prior to the study this should be continued. - complication of CRS (f.ex. mucocele, invasive fungal rhinosinusitis). Take sinus CT/CBCT scans, if needed! - acute rhinosinusitis/respiratory infection - severe disease related to airways/ immunology: cystic fibrosis, primary ciliary dyskinesia (PCD), sarcoidosis, immunosuppression, diagnosed Specific antibody deficiency (SAD), CVI, HIV, fungal rhinosinusitis; Young syndrome; Kartagener syndrome; - other severe disease such as active cancer - Received biologic therapy/systemic immunosuppressant/ASA desensitization therapy/experimental monoclonal antibody treatment to treat inflammatory or autoimmune disease within 2 months of study entry or 5 half-lives, whichever is longer. The patient is allowed to use ASA dose <100 mg/day due to cardiovascular reasons after ASA desensitization. - current immunotherapy - communication problems (f.ge. neurological/psychiatric disease, language skills) - unlikely to comply - ASA-challenge negative. - History of hypersensitivity to mepolizumab or excipients in the formulation

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Mepolizumab
Solution. Subcutaneous. Mepolizumab is a biological drug, a humanized monoclonal antibody against interleukin-5.
Placebo
Solution. Subcutaneous.

Locations

Country Name City State
Finland Helsinki University Hospital Helsinki

Sponsors (1)

Lead Sponsor Collaborator
Helsinki University Central Hospital

Country where clinical trial is conducted

Finland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change From Baseline at Week 16 in Sinonasal Outcome Test -22 (SNOT-22) Score SNOT-22 is a validated symptom questionnaire. The score ranges between 0 and 110. A higher score means worse outcome. Baseline, Week 16
Primary Change From Baseline at Week 16 in endoscopic Nasal polyp score of nasal cavity Nasal polyp score is graded based on polyp size from 0 = no polyps to 4 = large polyps causing complete obstruction of inferior nasal cavity. The score ranges between 0 and 110. A higher score means worse outcome.The Nasal polyp score FEV1% is measured by spirometry. A higher value means better lung function = better outcome. Baseline, Week 16
Secondary Change From Baseline at Week 16 in relative Forced expiatory volume in 1 second (FEV1 %) without bronchodilator. FEV1% is measured by spirometry. It is the volume of air (in liters) exhaled in the first second during forced exhalation after maximal inspiration, in relation to the validated national reference value of subjects with similar age, gender and height. Baseline, Week 16
See also
  Status Clinical Trial Phase
Recruiting NCT05895929 - The Role of IL5 in Epithelial Cell Integrity Early Phase 1
Active, not recruiting NCT05891483 - Efficacy and Safety of SHR-1905 Injection in Patients With Chronic Rhinosinusitis With Nasal Polyps Phase 2
Active, not recruiting NCT04998604 - EValuating trEatment RESponses of Dupilumab Versus Omalizumab in Type 2 Patients Phase 4
Recruiting NCT06069310 - Mepolizumab Effectiveness in Patients With Chronic Rhinosinusitis, Nasal Polyps and Comorbid Severe Eosinophilic Asthma
Recruiting NCT05009758 - Moving Towards Precision Medicine in United Airways Disease: Unraveling Inflammatory Patterns in Asthmatic Patients With or Without Nasal Polyps N/A
Active, not recruiting NCT05529784 - Dupilumab in the Treatment of Severe Uncontrolled CRSwNP: a Multicentre Observational Real-life Study (DUPIREAL)
Recruiting NCT05902325 - Identifying Predictors Of Response To Mepolizumab In CRSwNP Phase 4
Completed NCT05049122 - Dupilumab in Japanese Patients With Chronic Rhinosinusitis With Nasal Polyp (SINUS-M52) Phase 4
Not yet recruiting NCT05598411 - CST1-Guided Oral Glucocorticoids Management for CRSwNP Phase 4
Active, not recruiting NCT05553951 - Adherence in Global Airways N/A
Recruiting NCT05131464 - The Study of CM310 in Patients With Chronic Rhinosinusitis With Nasal Polyps Phase 2
Recruiting NCT05598424 - CST1 Predictive Model of Oral Glucocorticoid Therapy Sensitivity for Chronic Rhinosinusitis With Polyps Phase 4
Active, not recruiting NCT05649813 - A Study in Male and Female Adult Participants With Chronic Rhinosinusitis With Nasal Polyps In the Greater Gulf Region
Recruiting NCT04628442 - Tissue Immune Interaction in Nasal Polyposis
Active, not recruiting NCT06118554 - 3D Printing to Improve Nasal Irrigation Outcome N/A
Active, not recruiting NCT04596189 - Dupilumab for Prevention of Recurrence of CRSwNP After ESS Phase 4
Recruiting NCT02668861 - Effect of Oral Vitamin D3 on Chronic Rhinosinusitis Treatment in Adults With Lower Vitamin D Levels Phase 3
Active, not recruiting NCT05878093 - Dupilumab in Chinese Adult Participants With CRSwNP Phase 3
Completed NCT05931744 - The Role of Budesonide Intrapolyp Injection in the Management of Type 2 Chronic Rhinosinusitis Phase 2/Phase 3
Recruiting NCT05938972 - Real Life Study of Biologicals in Patients With Severe CRSwNP